Other news
First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer
The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...
Cooperation RTM-Alliance Medical
It is with great pleasure that we announce our cooperation with Alliance Medical Group (AMG) regardi...
RTM receives marketing authorisation for Fludeoxyglucose (18F)
We are happy to announce that RTM has received marketing authorization for 18F-FDG of 17 July 2018....
18F-FDOPA now available
Fluorodopa (18F) is now available for clinical studies and - with doctor's certificate - for routine...
Interested in a collaboration?
Contact us to discuss the possibilities.